We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sarossa | SARS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.52 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.52 | 1.52 |
| Top Posts |
|---|
Posted at 19/11/2015 11:44 by johnsmith321 Hi Hlp_4U,I agree with you a revaluation is needed as SLN has halved in price since the last annual report. They bought £4M of SLN at 200p, then 300K at 240p. PHC is down 20%. GVC is also down. I think more than a £2M loss will be seen in the P+L unfortunately. I guess they may need to do more buybacks this years otherwise the NAV per share will be way down as well. GVC will go back to 450p once the overhang of people who do not like the merger/dividend holiday go. The same thing happened at Optimal payments. Once the merger is completed, it will lead to a improvement in price as will the move to the main market. How low (1.5p) are the BOD going to let Sarossa go before they do something. The original Sarossa cornerstone investors are way down. They need to bring in another cornerstone investor to hover up the overhang in shares otherwise this will continue down. In Adams plc, cornerston investors own 89.6%. I think they should have the same arrangement. |
Posted at 22/10/2015 16:05 by johnsmith321 David H Richardson, who was also a director and now major investor in Adam plc has now increased his stake here (4.04%). He clearly has a positive opinion of what can happen in a small investment company with 4 years of rising profits, EPS and NAV per share.Lets hope we see 2.4p soon. |
Posted at 24/7/2015 10:45 by johnsmith321 David H Richardson has entered as a new investor (3.75%). He is also in with Griffiths in adams plc. This is encouraging as it suggests there is still more upside to come. |
Posted at 04/5/2003 09:05 by a harris US specialist eyes Powderject Boots THREADNEEDLE AFTER one false start it looks as though Britain’s leading vaccine specialist will finally succumb to the advances of United States group Chiron. Powderject has so far refused to confirm the identity of the mystery bidder. But the betting among industry sources is that the US firm has come back to the negotiating table and is this time willing to stump up around 545p or 550p a share - valuing the business at around £500m and substantially higher than last year’s offer which valued it at around £455m. Discussions last year foundered on price, but they are unlikely to do so this time. A deal undoubtedly makes sense between the two: both are vaccine specialists and, although from California, Chiron’s main trading is in Europe, while Powderject’s is in North America. A deal would also make sense for founder Paul Drayson who, no doubt, would be glad to get out of the limelight for a while after coming in for a barrage of criticism after his donations to the Labour party. These were made while his company was negotiating and securing a multi-million pound deal to supply the National Health Service with a smallpox vaccine. Drayson and his family also look set to walk away with a cool £83m if the deal does come off - a sum not to be sniffed at and enough to help start another biotechnology venture, should he feel like it. Given the fit between the two companies, the probability of a bidding war ensuing looks unlikely at this stage - although one should never say never. Nevertheless, with no other bidder currently at the table, it looks like Chiron’s offer is the only one in town - which makes it tricky for investors if the talks do collapse for the second time. The shares have already had quite a good run in recent weeks as takeover speculation has resurfaced and investors should, therefore, look to hedge any risks by taking some profits now rather than wait for any official confirmation in a few weeks time. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
